Medicenna Therapeutics Corp (MDNAF)
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing and commercializing Superkines and empowered Superkines for cancer, inflammation, and immune-mediated diseases. Its pipeline includes bizaxofusp, an IL-4 targeted therapy being developed for recurrent glioblastoma, as well as MDNA11, a long-acting IL-2 designed to stimulate anti-cancer immune cells while limiting the activity of immunosuppressive Tregs. Other programs include MDNA209, an IL-2/IL-15 antagonist under development for autoimmune conditions such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist for cancer immunotherapy; MDNA113, a tumor-targeting masked anti-PD-1-IL-2 BiSKITTM candidate; and MDNA132, an IL-13 Superkine for various tumors. The company is headquartered in Toronto, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MDNA.F
|
$0.21
|
-14.2% Downside
|
Fair
|
$3.25 1,217.9% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-1.8x
|
13.0x
|
—
|
22.976 M
|
18.811 M
|
0.4%
|
80.6%
|
-65.0
|
—
|
97.4%
|
